Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
47
ZBH Quote, Financials, Valuation and Earnings
Last price:
$90.80
Seasonality move
:
5.06%
Day range:
$89.86 - $91.03
52-week range:
$85.33 - $114.44
Dividend yield:
1.06%
P/E ratio:
22.46x
P/S ratio:
2.26x
P/B ratio:
1.41x
Volume:
967.5K
Avg. volume:
2.1M
1-year change:
-15.37%
Market cap:
$18B
Revenue:
$7.7B
EPS (TTM):
$4.04
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ZBH
Zimmer Biomet Holdings, Inc.
|
$2.1B | $1.92 | 9.9% | 100.01% | $102.04 |
|
EW
Edwards Lifesciences Corp.
|
$1.6B | $0.68 | 11.31% | -5.18% | $95.80 |
|
ISRG
Intuitive Surgical, Inc.
|
$2.6B | $2.12 | 12.86% | 19.35% | $599.60 |
|
NMTC
NeuroOne Medical Technologies Corp.
|
$2.2M | -- | -54.48% | -57.14% | $2.23 |
|
RMD
ResMed, Inc.
|
$1.4B | $2.77 | 8.96% | 16.17% | $291.80 |
|
SYK
Stryker Corp.
|
$6.3B | $3.06 | 10.64% | 210.62% | $428.11 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ZBH
Zimmer Biomet Holdings, Inc.
|
$90.77 | $102.04 | $18B | 22.46x | $0.24 | 1.06% | 2.26x |
|
EW
Edwards Lifesciences Corp.
|
$86.85 | $95.80 | $50.4B | 36.97x | $0.00 | 0% | 8.68x |
|
ISRG
Intuitive Surgical, Inc.
|
$577.81 | $599.60 | $204.8B | 76.48x | $0.00 | 0% | 21.86x |
|
NMTC
NeuroOne Medical Technologies Corp.
|
$0.73 | $2.23 | $36.8M | -- | $0.00 | 0% | 2.42x |
|
RMD
ResMed, Inc.
|
$244.76 | $291.80 | $35.7B | 25.05x | $0.60 | 0.92% | 6.85x |
|
SYK
Stryker Corp.
|
$354.22 | $428.11 | $135.5B | 46.51x | $0.84 | 0.95% | 5.61x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ZBH
Zimmer Biomet Holdings, Inc.
|
38.87% | -0.489 | 41.53% | 1.20x |
|
EW
Edwards Lifesciences Corp.
|
6.42% | -0.140 | 1.55% | 2.86x |
|
ISRG
Intuitive Surgical, Inc.
|
-- | 1.065 | -- | 3.42x |
|
NMTC
NeuroOne Medical Technologies Corp.
|
3.64% | 2.039 | 0.6% | 3.40x |
|
RMD
ResMed, Inc.
|
12.15% | 0.692 | 2.12% | 1.89x |
|
SYK
Stryker Corp.
|
44.02% | 0.583 | 12.35% | 0.97x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ZBH
Zimmer Biomet Holdings, Inc.
|
$1.3B | $330.7M | 4.11% | 6.45% | 16.52% | $267.7M |
|
EW
Edwards Lifesciences Corp.
|
$1.2B | $433.1M | 12.34% | 13.19% | 27.89% | $516.2M |
|
ISRG
Intuitive Surgical, Inc.
|
$1.7B | $759.7M | 16.35% | 16.38% | 30.33% | $735.6M |
|
NMTC
NeuroOne Medical Technologies Corp.
|
$1.5M | -$1.4M | -83.42% | -89.54% | -50.02% | -$1.5M |
|
RMD
ResMed, Inc.
|
$808.9M | $462.3M | 22.25% | 25.6% | 34.62% | $411.5M |
|
SYK
Stryker Corp.
|
$3.7B | $1.4B | 7.89% | 14.06% | 22.52% | $1.4B |
Zimmer Biomet Holdings, Inc. vs. Competitors
-
Which has Higher Returns ZBH or EW?
Edwards Lifesciences Corp. has a net margin of 11.55% compared to Zimmer Biomet Holdings, Inc.'s net margin of 18.82%. Zimmer Biomet Holdings, Inc.'s return on equity of 6.45% beat Edwards Lifesciences Corp.'s return on equity of 13.19%.
Company Gross Margin Earnings Per Share Invested Capital ZBHZimmer Biomet Holdings, Inc.62.7% $1.16 $20.9B EWEdwards Lifesciences Corp.78.29% $0.50 $10.9B -
What do Analysts Say About ZBH or EW?
Zimmer Biomet Holdings, Inc. has a consensus price target of $102.04, signalling upside risk potential of 12.42%. On the other hand Edwards Lifesciences Corp. has an analysts' consensus of $95.80 which suggests that it could grow by 10.31%. Given that Zimmer Biomet Holdings, Inc. has higher upside potential than Edwards Lifesciences Corp., analysts believe Zimmer Biomet Holdings, Inc. is more attractive than Edwards Lifesciences Corp..
Company Buy Ratings Hold Ratings Sell Ratings ZBHZimmer Biomet Holdings, Inc.4 18 1 EWEdwards Lifesciences Corp.15 13 0 -
Is ZBH or EW More Risky?
Zimmer Biomet Holdings, Inc. has a beta of 0.615, which suggesting that the stock is 38.541% less volatile than S&P 500. In comparison Edwards Lifesciences Corp. has a beta of 0.968, suggesting its less volatile than the S&P 500 by 3.229%.
-
Which is a Better Dividend Stock ZBH or EW?
Zimmer Biomet Holdings, Inc. has a quarterly dividend of $0.24 per share corresponding to a yield of 1.06%. Edwards Lifesciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings, Inc. pays 21.66% of its earnings as a dividend. Edwards Lifesciences Corp. pays out -- of its earnings as a dividend. Zimmer Biomet Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ZBH or EW?
Zimmer Biomet Holdings, Inc. quarterly revenues are $2B, which are larger than Edwards Lifesciences Corp. quarterly revenues of $1.6B. Zimmer Biomet Holdings, Inc.'s net income of $231.2M is lower than Edwards Lifesciences Corp.'s net income of $292.3M. Notably, Zimmer Biomet Holdings, Inc.'s price-to-earnings ratio is 22.46x while Edwards Lifesciences Corp.'s PE ratio is 36.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings, Inc. is 2.26x versus 8.68x for Edwards Lifesciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZBHZimmer Biomet Holdings, Inc.2.26x 22.46x $2B $231.2M EWEdwards Lifesciences Corp.8.68x 36.97x $1.6B $292.3M
-
Which has Higher Returns ZBH or ISRG?
Intuitive Surgical, Inc. has a net margin of 11.55% compared to Zimmer Biomet Holdings, Inc.'s net margin of 28.31%. Zimmer Biomet Holdings, Inc.'s return on equity of 6.45% beat Intuitive Surgical, Inc.'s return on equity of 16.38%.
Company Gross Margin Earnings Per Share Invested Capital ZBHZimmer Biomet Holdings, Inc.62.7% $1.16 $20.9B ISRGIntuitive Surgical, Inc.66.36% $1.95 $17B -
What do Analysts Say About ZBH or ISRG?
Zimmer Biomet Holdings, Inc. has a consensus price target of $102.04, signalling upside risk potential of 12.42%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $599.60 which suggests that it could grow by 3.77%. Given that Zimmer Biomet Holdings, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe Zimmer Biomet Holdings, Inc. is more attractive than Intuitive Surgical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZBHZimmer Biomet Holdings, Inc.4 18 1 ISRGIntuitive Surgical, Inc.14 11 1 -
Is ZBH or ISRG More Risky?
Zimmer Biomet Holdings, Inc. has a beta of 0.615, which suggesting that the stock is 38.541% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.249%.
-
Which is a Better Dividend Stock ZBH or ISRG?
Zimmer Biomet Holdings, Inc. has a quarterly dividend of $0.24 per share corresponding to a yield of 1.06%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings, Inc. pays 21.66% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. Zimmer Biomet Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ZBH or ISRG?
Zimmer Biomet Holdings, Inc. quarterly revenues are $2B, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.5B. Zimmer Biomet Holdings, Inc.'s net income of $231.2M is lower than Intuitive Surgical, Inc.'s net income of $709.2M. Notably, Zimmer Biomet Holdings, Inc.'s price-to-earnings ratio is 22.46x while Intuitive Surgical, Inc.'s PE ratio is 76.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings, Inc. is 2.26x versus 21.86x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZBHZimmer Biomet Holdings, Inc.2.26x 22.46x $2B $231.2M ISRGIntuitive Surgical, Inc.21.86x 76.48x $2.5B $709.2M
-
Which has Higher Returns ZBH or NMTC?
NeuroOne Medical Technologies Corp. has a net margin of 11.55% compared to Zimmer Biomet Holdings, Inc.'s net margin of -59.08%. Zimmer Biomet Holdings, Inc.'s return on equity of 6.45% beat NeuroOne Medical Technologies Corp.'s return on equity of -89.54%.
Company Gross Margin Earnings Per Share Invested Capital ZBHZimmer Biomet Holdings, Inc.62.7% $1.16 $20.9B NMTCNeuroOne Medical Technologies Corp.55.77% -$0.03 $7.3M -
What do Analysts Say About ZBH or NMTC?
Zimmer Biomet Holdings, Inc. has a consensus price target of $102.04, signalling upside risk potential of 12.42%. On the other hand NeuroOne Medical Technologies Corp. has an analysts' consensus of $2.23 which suggests that it could grow by 204.92%. Given that NeuroOne Medical Technologies Corp. has higher upside potential than Zimmer Biomet Holdings, Inc., analysts believe NeuroOne Medical Technologies Corp. is more attractive than Zimmer Biomet Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZBHZimmer Biomet Holdings, Inc.4 18 1 NMTCNeuroOne Medical Technologies Corp.1 0 0 -
Is ZBH or NMTC More Risky?
Zimmer Biomet Holdings, Inc. has a beta of 0.615, which suggesting that the stock is 38.541% less volatile than S&P 500. In comparison NeuroOne Medical Technologies Corp. has a beta of 0.703, suggesting its less volatile than the S&P 500 by 29.673%.
-
Which is a Better Dividend Stock ZBH or NMTC?
Zimmer Biomet Holdings, Inc. has a quarterly dividend of $0.24 per share corresponding to a yield of 1.06%. NeuroOne Medical Technologies Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings, Inc. pays 21.66% of its earnings as a dividend. NeuroOne Medical Technologies Corp. pays out -- of its earnings as a dividend. Zimmer Biomet Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ZBH or NMTC?
Zimmer Biomet Holdings, Inc. quarterly revenues are $2B, which are larger than NeuroOne Medical Technologies Corp. quarterly revenues of $2.7M. Zimmer Biomet Holdings, Inc.'s net income of $231.2M is higher than NeuroOne Medical Technologies Corp.'s net income of -$1.6M. Notably, Zimmer Biomet Holdings, Inc.'s price-to-earnings ratio is 22.46x while NeuroOne Medical Technologies Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings, Inc. is 2.26x versus 2.42x for NeuroOne Medical Technologies Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZBHZimmer Biomet Holdings, Inc.2.26x 22.46x $2B $231.2M NMTCNeuroOne Medical Technologies Corp.2.42x -- $2.7M -$1.6M
-
Which has Higher Returns ZBH or RMD?
ResMed, Inc. has a net margin of 11.55% compared to Zimmer Biomet Holdings, Inc.'s net margin of 26.1%. Zimmer Biomet Holdings, Inc.'s return on equity of 6.45% beat ResMed, Inc.'s return on equity of 25.6%.
Company Gross Margin Earnings Per Share Invested Capital ZBHZimmer Biomet Holdings, Inc.62.7% $1.16 $20.9B RMDResMed, Inc.60.56% $2.37 $7B -
What do Analysts Say About ZBH or RMD?
Zimmer Biomet Holdings, Inc. has a consensus price target of $102.04, signalling upside risk potential of 12.42%. On the other hand ResMed, Inc. has an analysts' consensus of $291.80 which suggests that it could grow by 19.22%. Given that ResMed, Inc. has higher upside potential than Zimmer Biomet Holdings, Inc., analysts believe ResMed, Inc. is more attractive than Zimmer Biomet Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZBHZimmer Biomet Holdings, Inc.4 18 1 RMDResMed, Inc.8 7 1 -
Is ZBH or RMD More Risky?
Zimmer Biomet Holdings, Inc. has a beta of 0.615, which suggesting that the stock is 38.541% less volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.363%.
-
Which is a Better Dividend Stock ZBH or RMD?
Zimmer Biomet Holdings, Inc. has a quarterly dividend of $0.24 per share corresponding to a yield of 1.06%. ResMed, Inc. offers a yield of 0.92% to investors and pays a quarterly dividend of $0.60 per share. Zimmer Biomet Holdings, Inc. pays 21.66% of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ZBH or RMD?
Zimmer Biomet Holdings, Inc. quarterly revenues are $2B, which are larger than ResMed, Inc. quarterly revenues of $1.3B. Zimmer Biomet Holdings, Inc.'s net income of $231.2M is lower than ResMed, Inc.'s net income of $348.5M. Notably, Zimmer Biomet Holdings, Inc.'s price-to-earnings ratio is 22.46x while ResMed, Inc.'s PE ratio is 25.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings, Inc. is 2.26x versus 6.85x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZBHZimmer Biomet Holdings, Inc.2.26x 22.46x $2B $231.2M RMDResMed, Inc.6.85x 25.05x $1.3B $348.5M
-
Which has Higher Returns ZBH or SYK?
Stryker Corp. has a net margin of 11.55% compared to Zimmer Biomet Holdings, Inc.'s net margin of 14.18%. Zimmer Biomet Holdings, Inc.'s return on equity of 6.45% beat Stryker Corp.'s return on equity of 14.06%.
Company Gross Margin Earnings Per Share Invested Capital ZBHZimmer Biomet Holdings, Inc.62.7% $1.16 $20.9B SYKStryker Corp.61.86% $2.22 $38.9B -
What do Analysts Say About ZBH or SYK?
Zimmer Biomet Holdings, Inc. has a consensus price target of $102.04, signalling upside risk potential of 12.42%. On the other hand Stryker Corp. has an analysts' consensus of $428.11 which suggests that it could grow by 20.86%. Given that Stryker Corp. has higher upside potential than Zimmer Biomet Holdings, Inc., analysts believe Stryker Corp. is more attractive than Zimmer Biomet Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZBHZimmer Biomet Holdings, Inc.4 18 1 SYKStryker Corp.13 9 0 -
Is ZBH or SYK More Risky?
Zimmer Biomet Holdings, Inc. has a beta of 0.615, which suggesting that the stock is 38.541% less volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.890, suggesting its less volatile than the S&P 500 by 11.047%.
-
Which is a Better Dividend Stock ZBH or SYK?
Zimmer Biomet Holdings, Inc. has a quarterly dividend of $0.24 per share corresponding to a yield of 1.06%. Stryker Corp. offers a yield of 0.95% to investors and pays a quarterly dividend of $0.84 per share. Zimmer Biomet Holdings, Inc. pays 21.66% of its earnings as a dividend. Stryker Corp. pays out 41.74% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ZBH or SYK?
Zimmer Biomet Holdings, Inc. quarterly revenues are $2B, which are smaller than Stryker Corp. quarterly revenues of $6.1B. Zimmer Biomet Holdings, Inc.'s net income of $231.2M is lower than Stryker Corp.'s net income of $859M. Notably, Zimmer Biomet Holdings, Inc.'s price-to-earnings ratio is 22.46x while Stryker Corp.'s PE ratio is 46.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings, Inc. is 2.26x versus 5.61x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZBHZimmer Biomet Holdings, Inc.2.26x 22.46x $2B $231.2M SYKStryker Corp.5.61x 46.51x $6.1B $859M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
